Table 2.
Ongoing or planned trials of antihypertensive deprescribing
| Trial name | Country | Study design | Age group | Sample size | Population | SBP eligibility criteria | Intervention | Primary outcome | Planned completion date |
|---|---|---|---|---|---|---|---|---|---|
| DANTON | Netherlands | RCT | Not specified | 492 | Nursing home residents with dementia | < 160 mmHg | Antihypertensive discontinuation | Neuropsychiatric symptoms/quality of life | 2022 |
| OPTiMISE-X | UK | RCT (passive follow-up) | ≥ 80 years | 569 | Community dwelling | < 150 mmHg | Medication reduction (one drug only) | All-cause hospitalisation or death | 2023 |
| RETREAT-FRAIL | France | RCT | ≥ 80 years | 1100 | Nursing home residents | < 130 mmHg | Step-down medication reduction | All-cause mortality | 2024 |
| OptimizeBP | Canada | RCT | ≥ 70 years | 383 | Nursing home residents | < 135 mmHg | Step-down medication reduction | All-cause mortality | 2024 |
| OPTIMISE2 | UK | RCT | ≥ 75 years | 3014 | Community dwelling at high risk of adverse events | < 150 mmHg | Step-down medication reduction | All-cause Emergency hospitalisation | 2027 |
SBP systolic blood pressure, RCT randomised controlled trial